Lexeo net loss narrows to $25.9 million in Q2 FY26; R&D expenses rise to $19 million

Reuters2026/08/12 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lexeo reported a Q2 2026 net loss of USD 25.9 million, narrowing from a USD 26.1 million loss a year earlier.
Loss per share improved to USD 0.30 from USD 0.60 in the prior-year quarter.
R&D expense rose 29.27% to USD 19 million, while G&A expense dropped 43.66% to USD 9 million.
Cash, cash equivalents, and investments totaled USD 234.2 million at June 30, 2026, with runway expected into 2028.
Initiated SUNRISE-FA 2 for LX2006 in June; topline data expected in H2 2027, with potential accelerated-approval BLA in H1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lexeo net loss narrows to $25.9 million in Q2 FY26; R&D expenses rise to $19 million

You may also like

Crypto prices